FAQs on Health Spending, the Federal Budget, and Budget Enforcement Tools March 20, 2023 Issue Brief As some policymakers in Washington are pushing to reduce the federal deficit and debt, this brief provides a concise explanation of federal spending for domestic and global health programs and services, which could be part of any conversation about curbing federal spending. These FAQs answer basic questions about health spending and the federal budget and budget enforcement tools, including the debt limit and sequestration.
As Debate Heats Up in Washington Over Possible Entitlement Cuts, A New KFF Analysis Details the 30% of Federal Spending That Goes to Health Care Programs March 1, 2023 News Release As some policymakers in Washington are pushing to reduce the federal deficit and debt, a new KFF resource provides a concise explanation of federal spending for domestic and global health programs and services, which could be part of any conversation about curbing federal spending. Federal spending on health programs and…
KFF Health Tracking Poll March 2023: Public Doesn’t Want Politicians To Upend Popular Programs March 30, 2023 Poll Finding Large majorities of the public hold favorable views of Medicare and Medicaid. While most people worry about Medicare’s sustainability for the future, they also view the debate in Washington about Medicare cuts as largely politics.
KFF Health Tracking Poll May 2024: Voters’ Views of Health Policy Issues in Context of Presidential Campaigns May 15, 2024 Poll Finding Voters are split largely along partisan lines in terms of who they trust in regard to various health care issues, but Biden captures more than Trump trust from Independent voters. Biden is also more trusted by older adults when it comes to entitlement programs. Voters are still largely unaware of the drug pricing provisions of the Inflation reduction Act. Large majorities of voters, particularly Democratic voters, support a federal right to abortion.
The CBO Report That Didn’t Roar January 4, 2024 From Drew Altman In his latest column, KFF President and CEO Drew Altman discusses a recent Congressional Budget Office (CBO) estimate that the Centers for Medicare and Medicaid Innovation (CMMI)’s payment and delivery demonstrations have cost Medicare money, and what it means for the future of value-based payment.
Nearly 7 in 10 Medicare Beneficiaries Did Not Compare Plans During Medicare’s Open Enrollment Period September 26, 2024 Issue Brief This brief examines the share of Medicare beneficiaries who reviewed their coverage and compared plans during the open enrollment period for 2022 (that takes place in the Fall of 2021), and who made use of Medicare’s official information resources, as well as variations by demographic groups. Overall, nearly 7 in 10 Medicare beneficiaries did not compare their own source of Medicare coverage with other Medicare options offered in their area.
Medicare Part D Premiums Are Increasing for Many But Not All Stand-Alone Plans in 2025, Reflecting Effects of New Premium Stabilization Demonstration October 3, 2024 Blog This policy watch examines monthly premiums for Medicare Part D stand-alone drug plans in 2025, as changes to the Part D benefit are being implemented in 2025, including a new $2,000 cap on out-of-pocket drug spending.
Health Policy is Partisan, But It’s Also Personal October 7, 2024 From Drew Altman In his latest column, KFF President and CEO Drew Altman explores how America’s big health care programs — Medicaid, Medicare, and the Affordable Care Act (ACA) — provide popular benefits valued by Americans from across the political spectrum. As partisan debates move closer to legislation, people may focus more on their personal financial concerns.
The Role Health PLAYED in the Election October 16, 2024 From Drew Altman In his latest column, KFF President and CEO Drew Altman provides an early post-mortem on the role health played in the election, discussing the many ways it did play a role in the campaign — even if not a decisive one.
The Effect of Delaying the Selection of Small Molecule Drugs for Medicare Drug Price Negotiation April 16, 2025 Blog In a new Trump administration executive order, the Secretary of HHS is directed to work with Congress to implement a change in law to delay negotiation of so-called “small molecule” drugs under the Inflation Reduction Act’s Medicare Drug Price Negotiation Program for an additional 4 years. This brief analyzes how many of the drugs previously selected for negotiation would not have been eligible if this policy had been in place at the time.